Eris Lifesciences Limited - Asset Resilience Ratio

Latest as of September 2025: 0.58%

Eris Lifesciences Limited (ERIS) has an Asset Resilience Ratio of 0.58% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ERIS total debt and obligations for a breakdown of total debt and financial obligations.

Liquid Assets

Rs415.50 Million
≈ $4.49 Million USD Cash + Short-term Investments

Total Assets

Rs71.60 Billion
≈ $774.32 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2012–2025)

This chart shows how Eris Lifesciences Limited's Asset Resilience Ratio has changed over time. See ERIS book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Eris Lifesciences Limited's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Eris Lifesciences Limited.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs136.90 Million 0.19%
Short-term Investments Rs278.60 Million 0.39%
Total Liquid Assets Rs415.50 Million 0.58%

Asset Resilience Insights

  • Limited Liquidity: Eris Lifesciences Limited maintains only 0.58% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Eris Lifesciences Limited Industry Peers by Asset Resilience Ratio

Compare Eris Lifesciences Limited's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Changchun High & New Technology Industries Group Inc
SHE:000661
Drug Manufacturers - Specialty & Generic 3.73%
Yuhan Corp.
KO:000100
Drug Manufacturers - Specialty & Generic 0.99%
Tasly Pharmaceutical Group Co Ltd
SHG:600535
Drug Manufacturers - Specialty & Generic 9.09%
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
Drug Manufacturers - Specialty & Generic 0.02%
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
Drug Manufacturers - Specialty & Generic 0.01%
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
Drug Manufacturers - Specialty & Generic 26.36%
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
Drug Manufacturers - Specialty & Generic 0.29%
Cronos Group Inc
TO:CRON
Drug Manufacturers - Specialty & Generic 69.94%

Annual Asset Resilience Ratio for Eris Lifesciences Limited (2012–2025)

The table below shows the annual Asset Resilience Ratio data for Eris Lifesciences Limited.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-03-31 0.07% Rs50.00 Million
≈ $540.73K
Rs70.33 Billion
≈ $760.61 Million
-17.59pp
2024-03-31 17.66% Rs12.45 Billion
≈ $134.60 Million
Rs70.49 Billion
≈ $762.30 Million
+16.75pp
2023-03-31 0.91% Rs332.21 Million
≈ $3.59 Million
Rs36.67 Billion
≈ $396.61 Million
-6.26pp
2022-03-31 7.17% Rs1.63 Billion
≈ $17.62 Million
Rs22.72 Billion
≈ $245.72 Million
+6.33pp
2021-03-31 0.84% Rs153.99 Million
≈ $1.67 Million
Rs18.35 Billion
≈ $198.42 Million
-3.98pp
2020-03-31 4.82% Rs747.81 Million
≈ $8.09 Million
Rs15.52 Billion
≈ $167.88 Million
-15.45pp
2019-03-31 20.27% Rs3.15 Billion
≈ $34.06 Million
Rs15.54 Billion
≈ $168.02 Million
+13.85pp
2018-03-31 6.42% Rs937.89 Million
≈ $10.14 Million
Rs14.60 Billion
≈ $157.90 Million
-33.90pp
2017-03-31 40.33% Rs2.58 Billion
≈ $27.95 Million
Rs6.41 Billion
≈ $69.32 Million
+24.72pp
2016-03-31 15.61% Rs653.20 Million
≈ $7.06 Million
Rs4.19 Billion
≈ $45.27 Million
-3.77pp
2015-03-31 19.38% Rs692.40 Million
≈ $7.49 Million
Rs3.57 Billion
≈ $38.64 Million
-5.37pp
2014-03-31 24.75% Rs669.64 Million
≈ $7.24 Million
Rs2.71 Billion
≈ $29.26 Million
-2.32pp
2013-03-31 27.07% Rs465.00 Million
≈ $5.03 Million
Rs1.72 Billion
≈ $18.58 Million
+13.88pp
2012-03-31 13.18% Rs134.52 Million
≈ $1.45 Million
Rs1.02 Billion
≈ $11.04 Million
--
pp = percentage points

About Eris Lifesciences Limited

NSE:ERIS India Drug Manufacturers - Specialty & Generic
Market Cap
$1.95 Billion
Rs180.20 Billion INR
Market Cap Rank
#6376 Global
#281 in India
Share Price
Rs1322.90
Change (1 day)
+0.51%
52-Week Range
Rs1271.00 - Rs1847.70
All Time High
Rs1847.70
About

Eris Lifesciences Limited, together with its subsidiaries, provides domestic branded formulations for chronic and sub-chronic therapies in India and internationally. The company offers various branded formulations in various therapeutic areas, such as anti"diabetes, cardiovascular, nutrition, dermatology, neuroscience, gynecology, nephrology, and oncology, as well as central nervous system, women… Read more